Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc.
  • Home
  • Our Coordinated Expression
    • Overview
    • Our Culture, Mission & Values
    • Our Commitment to Diversity, Equity & Inclusion
    • Message from BIO
  • Our People
    • Overview
    • Leadership
    • Board of Directors
    • Founders
  • Programs
    • Overview
    • Tamibarotene
    • SY-2101
    • SY-5609
    • Expanded Access Policy
  • Platform
    • Overview
    • What is Gene Control?
    • Publications and Abstracts
  • Patients
  • Investors & Media
  • Partners
  • Careers
  • Blog
  • Contact
Platform

Platform

  • Overview
  • What is Gene Control?
  • Publications and Abstracts

Publications and Abstracts

All Publications SY-2101 Publications SY-5609 Publications Tamibarotene Publications

sy-2101 Publications

ORAL ARSENIC TRIOXIDE ORH-2014 PHARMACOKINETIC AND SAFETY PROFILE IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS

FARHAD RAVANDI, IPHIGENIA KOUMENIS, ANANDHI JOHRI, MARTIN TALLMAN, GAIL J. ROBOZ, STEPHEN STRICKLAND, GUILLERMO GARCIA-MANERO, GAUTAM BORTHAKUR, KIRAN NAQVI, MEGHAN MEYER, MADHU PUDIPEDDI, SIRISH NIDARMARTHY, KRIS VADDI AND HAGOP KANTARJIAN
HAEMATOLOGICA VOL. 105 NO. 6 (2020)
JUNE 2020

© 2023 Syros Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Terms of Use Sitemap
twitter logo linkedin logo